Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
4
×
life sciences
national blog main
patisiran
4
×
akcea therapeutics
alnylam pharmaceuticals
boston
drugs
fda
inotersen
national top stories
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
hereditary transthyretin amyloidosis
pfizer
san francisco blog main
san francisco top stories
vyndaqel
acute hepatic porphyrias
akin akinc
aminolevulinic acid
andrew fire
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
craig mello
dan ollendorf
givosiran
john berk
john maraganore
mary o'donnell
What
alnylam
4
×
fda
ago
drug
medicine
approved
patients
pharmaceuticals
rna
rnai
afternoon
akcea
alnylam’s
amyloidosis
approval
approve
attr
available
awaits
battle
biological
crossed
debilitating
decades
decision
discovered
disease
fingers
friday
genetic
gets
historic
history
indicated
interference
landmark
making
medicines
nod
ok
Language
Current search:
patisiran
×
alnylam
×
" clinical trials "
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision